Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.

South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease. 

After Moderna roared through 2021 on the strength of the company’s COVID-19 vaccine, the mRNA giant forged a partnership with Carisma Therapeutics to develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for different forms of cancer.

BioSpace reviewed a busy January 5th for collaboration announcements in the life sciences world.

Ovid Therapeutics has partnered with AstraZeneca for exclusive access to a library of early-stage small molecules that target the KCC2 transporter, including OV350 — the lead candidate. 

Angany entered a partnering agreement to evaluate the safety and efficacy of the French-Canadian pharmaceutical company’s lead peanut allergy biological candidate BP/AH-01 with the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children.

Biohaven Pharmaceutical Holding and Pfizer have partnered to market the Connecticut-based company’s migraine drug Nurtec ODT (rimegepant) outside of the United States once approved by global regulatory organizations.

Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.

Ashfield Engage, part of UDG Healthcare, announced a new strategic partnership with PeakData, a world-leading technology company delivering AI-fueled scientific landscape analysis through their ground-breaking technology platform.

Eli Lilly and Pfizer announced Oct. 27 that they ceased the development of tanezumab, a pain drug the two companies had been developing for osteoarthritis.